Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates, with exclusive worldwide commercial rights to three product candidates in clinical development for various central nervous system disorders.

Caps

How do you think VNDA will perform against the market?

Add Stock to CAPS Watchlist

All Players

170 Outperform
111 Underperform
 

All-Star Players

35 Outperform
35 Underperform
 

Wall Street

4 Outperform
1 Underperform
 

Top VNDA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rbitrage (91.61)
Submitted June 23, 2014

Company has an expensive drug approved to treat blind people who are concerned about being on the same 24-hr calendar as the rest of us. Nobody else has a drug a drug like it. The best part is that people who are blind are generally covered by… More

rknapton (69.88)
Submitted August 22, 2013

Short. Pharma company with declining revenues and losses widening.

VNDA VS S&P 500 (SPY)

Fools bullish on VNDA are also bullish on:

Fools bearish on VNDA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VNDA.

Recs

0
Member Avatar Eskilf (57.82) Submitted: 7/18/2018 12:35:49 PM : Outperform Start Price: $20.70 VNDA Score: -7.27

Z HR

Recs

0
Member Avatar benyboy (< 20) Submitted: 3/5/2015 9:23:22 AM : Outperform Start Price: $10.55 VNDA Score: +51.89

John Paulson

Recs

0
Member Avatar Haugurafpeningum (26.92) Submitted: 3/1/2015 12:57:53 PM : Outperform Start Price: $10.73 VNDA Score: +48.80

Corey Davis and Jason Butler target $22-28

Leaderboard

Find the members with the highest scoring picks in VNDA.

Score Leader

kinikanik

kinikanik (52.02) Score: +337.23

The Score Leader is the player with the highest score across all their picks in VNDA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
kinikanik 52.02 1/7/2013 Outperform 1Y $3.74 +437.43% +100.20% +337.23 0 Comment
BlacknGold2 63.58 10/19/2012 Outperform 5Y $3.74 +437.43% +102.23% +335.20 0 Comment
jtut20 63.69 1/15/2013 Outperform 5Y $3.97 +406.30% +99.09% +307.20 0 Comment
Terapixel 95.91 8/6/2012 Outperform 5Y $3.92 +412.76% +108.47% +304.28 0 Comment
csull23 83.25 4/28/2008 Outperform 5Y $3.96 +407.58% +116.57% +291.00 0 Comment
jmbring 74.38 4/26/2012 Outperform 3Y $4.35 +362.07% +110.23% +251.84 0 Comment
Win1966 32.03 2/1/2008 Outperform 3Y $4.30 +367.44% +120.61% +246.83 0 Comment
MadelineLeigh < 20 6/26/2008 Outperform 1Y $4.25 +372.94% +134.09% +238.85 0 Comment
Imhilion 37.14 4/16/2012 Outperform 5Y $4.51 +345.68% +111.83% +233.84 0 Comment
handoverhill < 20 5/14/2008 Outperform 3W $4.49 +347.66% +114.76% +232.90 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackLazardCapit 75.63 5/17/2013 Outperform NS $6.84 +193.86% +75.95% +117.91 0 Comment
TrackZacks < 20 8/27/2010 Underperform 3M $6.44 -51.09% +29.29% +80.38 11/9/2012 @ $3.15 1 Comment
trackhapoalim < 20 3/10/2010 Outperform NS $10.70 +87.85% +154.99% -67.14 0 Comment
TrackJefferies 79.34 3/4/2010 Outperform NS $10.85 +85.25% +159.66% -74.41 0 Comment
TrackEveillard 94.49 9/30/2007 Outperform NS $13.91 +44.50% +100.50% -56.00 1 Comment
TrackBofASec 92.44 9/10/2007 Outperform NS $14.30 -93.64% -15.10% -78.54 7/29/2008 @ $0.91 0 Comment
TrackJimCramer 85.64 3/21/2007 Underperform 3W $23.68 -15.12% +115.43% +130.55 0 Comment
TrackFBRCapitalM 87.70 2/14/2007 Outperform NS $27.77 -87.68% -13.47% -74.22 7/10/2008 @ $3.42 0 Comment

Featured Broker Partners


Advertisement